Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership DUBLIN, Jan. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 42nd annual J.P. Morgan healthcare conference on Monday, January 8, 2024. Geoff...
Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare...
Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE:...
The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of fiscal year 2024 of $0.69 per ordinary share. This...
Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal year...
The Symplicity™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure Approval is the culmination of ten years of clinical research and development of the...
According to a new survey from Medtronic and Morning Consult, respondents recognize potential of AI to enable earlier diagnosis and improve access to care DUBLIN, Nov. 13, 2023 /PRNewswire/ --...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2024 on Tuesday, November 21, 2023....
TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ --...